BlueRock Therapeutics
https://bluerocktx.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BlueRock Therapeutics
Bayer Puts Spotlight On Pharma Pipeline
The Leverkusen-based firm has been touting the potential of its pharmaceutical pipeline which it hopes will be able to help soften the blow of patent expiries on the blockbusters Xarelto and Eylea in the next few years.
Senti Bio Raises $105m Series B Round For CAR-NKs, Led By Leaps For Bayer
The investment is the latest in Bayer’s series of moves into cell and gene therapy, amid growing industry interest in CAR-NKs.
Bayer Bids To Be A Winner In Cell & Gene Therapy
The last six weeks have seen the acquisition of AskBio, the launch of a dedicated cell and gene therapy unit and a CAR-T pact with Atara. Bayer is taking the space very seriously.
Finance Watch: Billions In And Billions Out In Venture Capital Fundraising
Private Company Edition: The flood of venture capital into health care and life science firms continues with Perceptive closing a $1.1bn credit fund and Sanofi investing $50m in Jeito Capital. Also, Ambrx closed a $200m crossover round as biopharma remains on track for a record funding year.